Global Drugs for Xerostomia Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drugs for Xerostomia Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Drugs for Xerostomia include prescription and over-the-counter mouthwashes, artificial saliva or humectants to moisturize the mouth, mouthwashes specially for dry mouth, especially those containing xylitol
Drugs for Xerostomia report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs for Xerostomia market is projected to reach US$ 907.1 million in 2029, increasing from US$ 714 million in 2022, with the CAGR of 3.5% during the period of 2024 to 2029. Demand from Supermarket and Hospital are the major drivers for the industry.
Xerostomia, commonly referred to as "xerostomia syndrome," is the result of reduced or absent saliva flow, resulting in dry mucous membranes. Increase in radiation therapy and chemotherapy may lead to increased incidence of xerostomia, which is expected to primarily drive the xerostomia treatment market. Other factors driving the market growth include growing geriatric population base; rising prevalence of diseases such as HIV, diabetes, and Alzheimer's disease.
Furthermore, the geriatric population is expected to have a significant impact on the studied market. For example, according to the 2022 World Population Prospects, the global population aged 65 and over will be 771 million in 2022, and it is expected to reach 994 million by 2030 and 1.6 billion by 2050. Older adults often experience dry mouth, which is often associated with reduced salivary gland activity. Medication use, chronic disease, and radiation therapy to the head and neck area have all been cited as causes of xerostomia in older adults.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Xerostomia market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Concordia
AMICI
Aurobindo Pharma Ltd
Impax Labs
Lannett Co Inc
Padagis Us
Amneal Pharmaceuticals Pvt. Ltd.
Bausch Health Companies Inc.
GSK
Jazz Pharmaceuticals plc
Mission Pharmacal Company
OraCoat
Cumberland Pharmaceuticals, Inc.
Fleet, C.B., Company
Parnell Pharmaceuticals, Inc
Clinigen
Sun Pharm
Segment by Type
Spray
Oral Liquid
Buccal Tablet
Mouth Wash
Supermarket
Hospital
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Drugs for Xerostomia market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Drugs for Xerostomia, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Drugs for Xerostomia industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Drugs for Xerostomia in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Drugs for Xerostomia introduction, etc. Drugs for Xerostomia Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Drugs for Xerostomia market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Drugs for Xerostomia report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs for Xerostomia market is projected to reach US$ 907.1 million in 2029, increasing from US$ 714 million in 2022, with the CAGR of 3.5% during the period of 2024 to 2029. Demand from Supermarket and Hospital are the major drivers for the industry.
Xerostomia, commonly referred to as "xerostomia syndrome," is the result of reduced or absent saliva flow, resulting in dry mucous membranes. Increase in radiation therapy and chemotherapy may lead to increased incidence of xerostomia, which is expected to primarily drive the xerostomia treatment market. Other factors driving the market growth include growing geriatric population base; rising prevalence of diseases such as HIV, diabetes, and Alzheimer's disease.
Furthermore, the geriatric population is expected to have a significant impact on the studied market. For example, according to the 2022 World Population Prospects, the global population aged 65 and over will be 771 million in 2022, and it is expected to reach 994 million by 2030 and 1.6 billion by 2050. Older adults often experience dry mouth, which is often associated with reduced salivary gland activity. Medication use, chronic disease, and radiation therapy to the head and neck area have all been cited as causes of xerostomia in older adults.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Xerostomia market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Concordia
AMICI
Aurobindo Pharma Ltd
Impax Labs
Lannett Co Inc
Padagis Us
Amneal Pharmaceuticals Pvt. Ltd.
Bausch Health Companies Inc.
GSK
Jazz Pharmaceuticals plc
Mission Pharmacal Company
OraCoat
Cumberland Pharmaceuticals, Inc.
Fleet, C.B., Company
Parnell Pharmaceuticals, Inc
Clinigen
Sun Pharm
Segment by Type
Spray
Oral Liquid
Buccal Tablet
Mouth Wash
Segment by Application
Supermarket
Hospital
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Drugs for Xerostomia market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Drugs for Xerostomia, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Drugs for Xerostomia industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Drugs for Xerostomia in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Drugs for Xerostomia introduction, etc. Drugs for Xerostomia Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Drugs for Xerostomia market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices